Neurogene Files 8-K: Q4/FY25 Earnings & Corporate Presentation

Ticker: NGNE · Form: 8-K · Filed: Mar 24, 2026 · CIK: 0001404644

Neurogene Inc. 8-K Filing Summary
FieldDetail
CompanyNeurogene Inc. (NGNE)
Form Type8-K
Filed DateMar 24, 2026
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.000001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: earnings, financial-results, corporate-presentation

TL;DR

**Neurogene just dropped its Q4/FY25 earnings and a new corporate presentation, so get ready for potential stock movement.**

AI Summary

Neurogene Inc. filed an 8-K on March 24, 2026, to announce its results of operations and financial condition, specifically for the fourth quarter and year-end 2025. This filing includes an earnings release (EX-99.1) and a corporate presentation (EX-99.2), which likely contain key financial figures and strategic updates. For investors, this matters because it provides the latest financial health and future outlook of Neurogene, directly impacting stock valuation and investment decisions.

Why It Matters

This filing provides crucial financial updates for Neurogene Inc., allowing investors to assess the company's performance and future prospects. The included corporate presentation may offer insights into strategic direction and pipeline developments.

Risk Assessment

Risk Level: medium — The risk level is medium because while the filing announces financial results, the actual impact depends on the content of the earnings release and corporate presentation, which are not detailed here.

Analyst Insight

A smart investor would immediately review the attached EX-99.1 earnings release and EX-99.2 corporate presentation to understand Neurogene's financial performance for Q4 and year-end 2025, as well as any forward-looking statements or strategic updates, before making any investment decisions.

Key Players & Entities

  • Neurogene Inc. (company) — Filer of the 8-K
  • 0001404644 (company) — Filer CIK
  • 2026-03-24 (date) — Filing Date and Period of Report

FAQ

What specific financial information is included in this 8-K filing?

This 8-K filing, under Item 2.02, includes 'Results of Operations and Financial Condition' and references Exhibit 99.1, which is the 'ngne_4qye25earningsrelease.htm' (Neurogene's Q4 and year-end 2025 earnings release), and Exhibit 99.2, which is 'a202603_ngnecorporatepre.htm' (a corporate presentation).

When was this 8-K filing submitted and accepted by the SEC?

The 8-K filing was submitted and accepted by the SEC on March 24, 2026, at 07:31:15.

Filing Stats: 574 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2026-03-24 07:31:15

Key Financial Figures

  • $0.000001 — ange on which registered Common Stock, $0.000001 par value NGNE The Nasdaq Global Market

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On March 24, 2026, Neurogene Inc. (the "Company") issued a press release announcing financial results for the quarter and year ended December 31, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on March 24, 2026, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Item 2.02 and Exhibit s 99.1 and 99.2 attached hereto are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibit s 99.1 and 99.2 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated March 24, 2026 99.2 Corporate Presentation (March 2026) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: March 24, 2026 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.